Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2011, Pages 421-425

  Walkey, Allan J ^a   Fein, Daniel ^a   Horbowicz, Kevin J ^b   Farber, Harrison W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Epoprostenol; Pulmonary hypertension; Treprostinil

Indexed keywords

PROSTACYCLIN; UNIPROST;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CASE STUDY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMIC PARAMETERS; HUMAN; IDIOPATHIC DISEASE; INTENSIVE CARE UNIT; LUNG VASCULAR RESISTANCE; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STATISTICAL MODEL; SYSTEMIC SCLEROSIS;

ADULT; AGED; EPOPROSTENOL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 79956139731     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.01.002     Document Type: Article

References (14)

1. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American heart Association: developed in collaboration with the American College of Chest physicians, American Thoracic Society, Inc., and the pulmonary hypertension Association. Circulation 2009, 119:2250-2294. J Am Coll Cardiol. 2009; 53:1573-619.
2. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302. The Primary Pulmonary Hypertension Study Group.
3. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
4. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., Benza R.L., Widlitz A.C., Krichman A., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006, 129:683-688.
5. Hiremath J., Thanikachalam S., Parikh K., Shanmugasundaram S., Bangera S., Shapiro L., et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant 2010, 29:137-149. TRUST Study Group.
6. Gomberg-Maitland M., Tapson V.F., Benza R.L., McLaughlin V.V., Krichman A., Widlitz A.C., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir CritCare Med 2005, 172:1586-1589.
7. Laliberte K., Arneson C., Jeffs R., Hunt T., Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004, 44:209-214.
8. Sullivan L.M. Repeated measures. Circulation 2008, 117:1238-1243.
9. Reisbig K.A., Coffman P.A., Floreani A.A., Boltsma C.J., Olsen K.M. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension. Ann Pharmacother 2005, 39:739-743.
10. Aronoff D.M., Peres C.M., Serezani C.H., Ballinger M.N., Carstens J.K., Coleman N., et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 2007, 178:1628-1634.
11. Kallen A.J., Lederman E., Balaji A., Trevino I., Petersen E.E., Shoulson R., et al. Incidence of central line infection in pulmonary hypertension patients receiving prostanoids. Infect Control Hosp Epidemiol 2008, 29:332-339.
12. Miller O., Tang S., Keech A., Celermajer D. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 1995, 346:51-52.
13. Wade M., Baker F.J., Roscigno R., DellaMaestra W., Hunt T.L., Lai A.A. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 2004, 44:83-88.
14. Oudiz R.J., Farber H.W. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J 2009, 157:625-635.